NDAVAGINALGEL
Approved
Mar 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
NUVESSA (metronidazole) by Galderma is [see microbiology ( )]. Approved for bacterial vaginosis, intra-abdominal infection. First approved in 2014.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NUVESSA is a vaginal gel formulation of metronidazole, a nitroimidazole antimicrobial indicated for bacterial vaginosis and multiple systemic infections including intra-abdominal infections, rosacea, pelvic inflammatory disease, and Clostridioides difficile-associated diarrhea. The drug works by disrupting DNA synthesis in susceptible organisms through electron transfer within the nitroimidazole ring. NUVESSA represents a localized vaginal delivery approach to a well-established systemic agent.
$0.11MPart D
Peak6.1 years to LOEAt peak lifecycle with minimal Medicare Part D penetration ($110K annually), the product maintains stable but modest market presence; brand team is likely focused on maintenance and specialty segment optimization rather than growth expansion.
Mechanism of Action
[see Microbiology ( )].
Pharmacologic Class:
Nitroimidazole Antimicrobial
Indications (2)
Worked on NUVESSA at Galderma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.